-DOCSTART- -X- O
DNA -X- _ B-Intervention
vaccination -X- _ I-Intervention
has -X- _ O
been -X- _ O
developed -X- _ O
in -X- _ O
the -X- _ O
last -X- _ O
two -X- _ O
decades -X- _ O
in -X- _ O
human -X- _ O
and -X- _ O
animal -X- _ O
species -X- _ O
as -X- _ O
a -X- _ O
promising -X- _ O
alternative -X- _ O
to -X- _ O
conventional -X- _ O
vaccination. -X- _ O
It -X- _ O
consists -X- _ O
in -X- _ O
the -X- _ O
injection -X- _ O
, -X- _ O
in -X- _ O
the -X- _ O
muscle -X- _ O
, -X- _ O
for -X- _ O
example -X- _ O
, -X- _ O
of -X- _ O
plasmid -X- _ B-Intervention
DNA -X- _ I-Intervention
encoding -X- _ I-Intervention
the -X- _ I-Intervention
vaccinating -X- _ I-Intervention
polypeptide. -X- _ I-Intervention
Electroporation -X- _ B-Intervention
which -X- _ O
forces -X- _ O
the -X- _ O
entrance -X- _ O
of -X- _ O
the -X- _ O
plasmid -X- _ B-Intervention
DNA -X- _ I-Intervention
in -X- _ O
cells -X- _ O
at -X- _ O
the -X- _ O
injection -X- _ O
point -X- _ O
has -X- _ O
been -X- _ O
described -X- _ O
as -X- _ O
a -X- _ O
powerful -X- _ O
and -X- _ O
promising -X- _ O
strategy -X- _ O
to -X- _ O
enhance -X- _ O
DNA -X- _ O
vaccine -X- _ O
efficacy. -X- _ O
Due -X- _ O
to -X- _ O
the -X- _ O
fact -X- _ O
that -X- _ O
the -X- _ O
vaccine -X- _ O
is -X- _ O
composed -X- _ O
of -X- _ O
DNA -X- _ O
, -X- _ O
close -X- _ O
attention -X- _ O
on -X- _ O
the -X- _ O
fate -X- _ O
of -X- _ O
the -X- _ O
plasmid -X- _ B-Intervention
DNA -X- _ I-Intervention
upon -X- _ O
vaccination -X- _ O
has -X- _ O
to -X- _ O
be -X- _ O
taken -X- _ O
into -X- _ O
account -X- _ O
, -X- _ O
especially -X- _ O
at -X- _ O
the -X- _ O
injection -X- _ O
point. -X- _ O
To -X- _ O
perform -X- _ O
such -X- _ O
studies -X- _ O
, -X- _ O
the -X- _ O
muscle -X- _ O
injection -X- _ O
point -X- _ O
has -X- _ O
to -X- _ O
be -X- _ O
precisely -X- _ O
recovered -X- _ O
and -X- _ O
collected -X- _ O
several -X- _ O
weeks -X- _ O
after -X- _ O
injection. -X- _ O
This -X- _ O
is -X- _ O
even -X- _ O
more -X- _ O
difficult -X- _ O
for -X- _ O
large -X- _ O
and -X- _ O
growing -X- _ O
animals. -X- _ O
A -X- _ O
technique -X- _ O
has -X- _ O
been -X- _ O
developed -X- _ O
to -X- _ O
localize -X- _ O
precisely -X- _ O
and -X- _ O
collect -X- _ O
efficiently -X- _ O
the -X- _ O
muscle -X- _ O
injection -X- _ O
points -X- _ O
in -X- _ O
growing -X- _ B-Patient
piglets -X- _ I-Patient
6 -X- _ O
weeks -X- _ O
after -X- _ O
DNA -X- _ B-Intervention
vaccination -X- _ I-Intervention
accompanied -X- _ B-Comparison
or -X- _ I-Comparison
not -X- _ I-Comparison
by -X- _ I-Comparison
electroporation. -X- _ I-Comparison
Electroporation -X- _ B-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
significantly -X- _ I-Outcome
increase -X- _ I-Outcome
the -X- _ I-Outcome
level -X- _ I-Outcome
of -X- _ I-Outcome
remaining -X- _ I-Outcome
plasmids -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
nonelectroporated -X- _ I-Outcome
piglets -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
, -X- _ I-Outcome
in -X- _ I-Outcome
all -X- _ I-Outcome
the -X- _ I-Outcome
cases -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
levels -X- _ I-Outcome
were -X- _ I-Outcome
below -X- _ I-Outcome
the -X- _ I-Outcome
limit -X- _ I-Outcome
recommended -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
FDA -X- _ I-Outcome
to -X- _ I-Outcome
research -X- _ I-Outcome
integration -X- _ I-Outcome
events -X- _ I-Outcome
of -X- _ I-Outcome
plasmid -X- _ I-Outcome
DNA -X- _ I-Outcome
into -X- _ I-Outcome
the -X- _ I-Outcome
host -X- _ I-Outcome
DNA -X- _ I-Outcome
. -X- _ O

